================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2010
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
Nevada 0-15482 86-1006416
------------------------------ ---------- -----------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 - Other Events
There have been no material changes in the Company or its affairs since its
filing of its annual report on Form 10-K for the year ended August 31, 2009,
filed on March 17, 2010.
On March 22, 2010, it's the Company's Board of Directors authorized the
Company to split it's outstanding units into the securities comprising such
units. Each unit presently consists of: three shares of common stock; and one
share of Series A Convertible Preferred Stock. Each share of Series A
Convertible Preferred Stock is convertible into two shares of common stock at a
conversion price of $.10 per common share. An aggregate of 591,724 shares of
common stock are issuable upon conversion of the shares of Series A Convertible
Preferred Stock underlying the units. The Company will receive net proceeds of
approximately $59,000 assuming all of the shares of Series A Convertible
Preferred Stock are converted into shares of common stock.
Each holder's right to split the units into the underlying securities is
contingent upon the conversion of the underlying shares of Series A Convertible
Preferred Stock into common stock on or prior to April 30, 2010.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: March 24, 2010 ONCOLOGIX TECH, INC.
By: /s/ Anthony Silverman
----------------------------------
Anthony Silverman,
Chief Executive Officer and
President
By: /s/ Michael A. Kramarz
----------------------------------
Michael A. Kramarz,
Chief Financial Officer